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Abstract 
Objective:  The purpose of this systematic review is to determine the role misoprostol currently 
plays in the reduction of maternal deaths and implications for the future reduction of maternal 
deaths in low resource settings.  
Methods: A comprehensive review of the literature was performed using the following 
databases: The Cochrane Database, Ebsco, MEDLINE, PubMed, and Electronic Journal Center 
(EJC).  Articles were excluded based upon date published, overt data changes since publication, 
and setting of misoprostol interventions in tertiary or referral centers that have access to 
oxytocin.  A total of 61 articles were included from 2002-2012 and demonstrated several 
methodologies and study designs.  Review of several program field guides and position 
statements by key stakeholders were incorporated into this comprehensive literature review. 
Discussion: Postpartum hemorrhage accounts for nearly 25% of maternal deaths globally and is 
most likely to involve the poorest; most underserved, and marginalized women.  South Asia and 
Sub-Saharan Africa comprise the greatest numbers of these women.  Widespread use of 
misoprostol in the treatment and prevention of postpartum hemorrhage remains controversial.  
The lack of clarity and vigor by the WHO guidelines regarding the use of misoprostol for 
prevention of PPH at the community level has further impeded efforts aimed at the reduction of 
maternal deaths due to postpartum hemorrhage.  Task shifting strategies will play a crucial role 
to the successful implementation of community distribution programs that have been proven to 
save the lives of mothers in low resource areas where maternal deaths are the most profoundly 
experienced.  
 
Key Words: misoprostol, post-partum hemorrhage, maternal mortality, maternal death, 
low resource setting, task shifting and skilled birth attendant. 
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The Role of Misoprostol in the Reduction of Maternal Deaths in Low Resource Settings:   
A Systematic Review with Recommendations for Action 
Complications during pregnancy and childbirth are the leading cause of death and 
disability among women in low-income countries.  Women’s health is recognized as a 
fundamental human right in treaties such as the Convention on the Elimination of all Forms of 
Discrimination against Women [CEDAW], and the International Covenant on Economic, Social 
and Cultural Rights (Ki-moon, Ban, UN Secretary General, 2010).  A maternal death is defined 
as: “the death of a woman while pregnant or within 42 days of termination of pregnancy, 
irrespective of the duration and site of the pregnancy, from any cause related to or aggravated by 
the pregnancy or its management but not from accidental or incidental causes” (World Health 
Organization [WHO], 2010).  Maternal mortality is widely regarded as a key indicator of 
population health and of social and economic development, and in many countries in the region 
of Africa, between 25% and 33% of all deaths of women of reproductive age are the results of a 
complication of pregnancy or childbirth.  Whereas in industrialized countries the risk of maternal 
death is low, estimated at 1%, the high fertility rates and low contraceptive use in Africa 
contribute to this high risk (African Regional Reproductive Health Task Force, 2004).   
The World Health Organization and other agencies monitor levels and trends closely.  
This monitoring is a result, in part, by the United Nation's Millennium Development Goals 
[MDG’s], which call for a three-fourths reduction in the maternal mortality ratio between 1990 
and 2015 (Wilmoth et al., 2012).   
The Millennium Development Goals are the global objectives for addressing the many 
facets that define extreme poverty as well as ensuring the basic human rights of each person.  
The issue of maternal deaths is so pervasive and significant in the global arena that one MDG 
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specifically addresses this issue.  Millennium Development Goal 5 is to improve maternal health.  
In addition to a three-quarters reduction of maternal deaths, indicators of success include the 
proportion of births attended by skilled health personnel and the maternal mortality ratio as 
determined by UNICEF and the WHO (2006).  Universal access to reproductive health is the end 
goal.  Such a target implies that the maternal mortality ratio (MMR) should decline at an average 
rate of at least 5.5% per year over the 25-year interval (Wilmoth et al., 2012).  
A maternal death is thought of as one of life’s most tragic ends.  The death of a woman 
who is creating life is profoundly sad, and her death is an immeasurable loss for those living 
children and other family members who are left behind.  Such deaths are almost entirely 
preventable given proper medical surveillance and timely intervention, and as such maternal 
mortality is often viewed as a key indicator of the quality of a health care delivery system 
(Wilmoth et al., 2012).  Although maternal mortality rates have fallen in some areas of the world, 
global attainment of MDG 5 is doubtful (Requejo, Bryce, Deixel, & Victora, 2012).  Maternal 
mortality rates have decreased nearly 47% since 1990, however, nearly 287,000 mothers died in 
2010 (Medecins Sans Frontieres, 2012).  Of these deaths, approximately 245,000 deaths occurred 
in Southern Asia and Sub-Saharan Africa (Crowe, Utley, Costello, & Pagel, 2012).  These two 
regions of the world comprise 85% of this global burden.  
The areas around the world in which the greatest concentration of maternal deaths occur 
are often labeled “low resource”.  Remote villages in Sub-Saharan Africa and Southern Asia 
typify this term.  Women in these parts of the world often face poverty, discrimination, poor or 
nonexistent health care infrastructure, lack of access to secure means of communication and lack 
of reliable and consistent transportation (International Federation of Gynecology and Obstetrics 
Safe Motherhood and Newborn Health Committee [FIGO SMNHC], 2012).  A great percentage 
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of women in low-resource countries give birth at home or outside a structured health facility 
without immediate access to emergency obstetric care or a skilled birth attendant, thus making 
pregnant women more vulnerable to disability and death (Rushwan, 2011).  Maternal death rates 
in these low-resource areas reflect considerable disparities in regards to education, security, 
income and ultimately access to the most basic of maternal health care services (Lalonde, Daviss, 
Acosta, & Herschderfer, 2006).  
In order to impact the rate of maternal deaths, reduction efforts must be targeted at the 
most common complications that account for these deaths.  These are hemorrhage, sepsis, pre-
eclampsia, obstructed labor and unsafe abortion, with the greatest number of deaths as a result of 
hemorrhage (WHO, 2012a).  The focus of my systematic review is postpartum hemorrhage 
(PPH), as it is the single greatest cause of maternal deaths globally, accounting for nearly one 
quarter or roughly 71,000 deaths alone in 2010 (Coeytaux & Wells, 2011).   
Purpose Statement 
 The purpose of this systematic review is threefold: 1) Determine the role misoprostol 
currently plays in the reduction of maternal deaths secondary to postpartum hemorrhage, 2) 
Demonstrate the effectiveness of misoprostol use alone in the efforts to reduce maternal 
mortality, and 3) Explore implementation opportunities for the future reduction of maternal 
deaths in low resource settings.  
Methods 
A comprehensive review of the literature was performed using the following databases: 
The Cochrane Database, Ebsco, MEDLINE, PubMed, and Electronic Journal Center (EJC).  Key 
terms utilized include: maternal mortality, maternal deaths, low resource settings, postpartum 
hemorrhage, and treatment of postpartum hemorrhage, prevention of postpartum hemorrhage, 
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misoprostol, cost-effective strategies, and active management of the third stage of labor 
(AMTSL).  Total articles reviewed totaled 141.  Articles were excluded based upon date 
published, overt data changes since publication, and setting of misoprostol interventions in 
tertiary or referral centers that have access to oxytocin.  Articles included were published from 
2002-2012 and demonstrated several methodologies with total of 61 references included.  
Review of several program field guides and position statements by key stakeholders was also 
incorporated into this comprehensive literature review. 
 Key analyses include medical efficacy and safety, cost, feasibility, barriers, and 
implications for public health.  Studies were assigned a grade of internal validity utilizing the 
U.S. Preventive Services Task Force (USPSTF) Criteria for Grading the Internal Validity of 
Individual Studies (Harris et al., 2001) and conclusions were then determined.  It should be noted 
that evaluation based upon quality of internal validity alone provides only a limited assessment 
of interventions for the community-based settings in which public health interventions occur.  
The USPSTF additionally provides a systematic review that assesses external validity, magnitude 
of effect and certainty to translate the evidence of reviews into suggestions for practice 
(Brownson, Fielding, & Maylahn, 2009).  For the purpose of this systematic review of the 
literature, this evaluation scheme provided a framework for selection and organization of the data 
utilized in the compilation that was beneficial to this writer.  
Systematic Review 
Postpartum Hemorrhage 
Postpartum hemorrhage is defined as the loss of greater than 500ml of blood during the 
first 24 hours following delivery (WHO, 2007).  However, for clinical purposes, any blood loss 
that has the potential to produce hemodynamic instability should be considered a postpartum 
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hemorrhage, as clinical estimates of blood loss volumes are often inaccurate (FIGO, SMNHC, 
2012).  More recent definitions of postpartum hemorrhage make further delineation classified by 
the period of time following delivery.  Primary or immediate PPH occurs immediately following 
delivery, up to 24 hours.  Approximately 70% of cases involving primary PPH are caused by 
uterine atony (FIGO, SMNH Committee, 2012).  Atony of the uterus is defined as insufficient 
contractility of the uterus following delivery.  A less likely type of PPH is known as secondary or 
late PPH.  This type of hemorrhage occurs between 24 hours following delivery up to 6 weeks 
postpartum.  Secondary PPH is most often due to infection, retained products of conception, or 
both (FIGO, SMNH Committee, 2012).  The most likely period at which postpartum hemorrhage 
occurs is during the third stage of labor.  This stage describes the period of time following 
delivery of the baby, but prior to delivery of the placenta, when the uterus is most likely to 
experience atony.  The third stage of labor is the period of time in which interventions targeted at 
preventing or treating postpartum hemorrhage becomes crucial.  Without immediate medical 
treatment, a woman that suffers from hemorrhage following childbirth will likely die within two 
hours (Family Care International, 2006).  Intervening successfully to treat postpartum 
hemorrhage becomes an even greater challenge in the face of such a short window of time.  
Knowing that postpartum hemorrhage is almost always preventable must not be overlooked.  
Prevention Strategies 
Strategies to reduce maternal mortality in recent years have extended along the 
continuum of care from low technological, low cost interventions to the high technology, high 
resource and high cost interventions commonplace in developed areas of the world.  Because the 
environments in which women deliver babies is diverse, the approaches to PPH treatment and 
prevention will also require diversity (FIGO, SMNHC, 2012).  Interventions that might be 
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considered high technology range from the reorganization of health systems, the systematic 
strengthening of midwifery skills, and increasing the number of skilled birth attendants in low 
resource settings.  
Examples of low technology, well-established interventions include immediate 
breastfeeding of the newborn (within the first hour after birth), which triggers strong uterine 
contractions and is life saving for the newborn (Edmond et al., 2006; Edmond, Kirkwood, 
Tawiah, & Agyei, 2008).  The WHO-UNICEF Baby-Friendly Hospital Initiative (BFHI) Step 4 
states "Help mothers initiate breastfeeding within one hour of birth" (WHO and UNICEF, 2009, 
Section 4, pg. 11).  Further discussion of immediate breastfeeding as a strategy for reducing or 
preventing postpartum hemorrhage is beyond the scope of this analysis.  Additional examples of 
low technology programs implemented include: the use of pads to accurately measure blood loss 
following delivery, and the placement of a non-pneumatic anti-shock garment to treat postpartum 
hemorrhage, have also been noted.  Field guides recommend delivery kits with clean cords and 
plastic pads for use during delivery (Family Care International, 2006).  Recent efforts to reduce 
maternal mortality in low resource countries have prioritized two key strategies: training and 
deploying skilled birth attendants (SBAs), and improving access to emergency obstetric care.  
Both strategies have been repeatedly shown to improve maternal and child health outcomes 
(Prata et al., 2011).  Current maternal death rates demonstrate that these strategies alone are 
insufficient.  These strategies do not address the safe-delivery needs of women living in remote 
communities, who are less likely to have access to either SBAs or emergency obstetric care 
(Prata et al., 2011).  
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Safe Motherhood Agendas 
While increasing access to a standardized health care structure to include access to skilled 
birth attendants is an admirable goal, the proportion of births actually attended by a SBA is 
unlikely to change substantially for several decades (Prata et al., 2012b).  The authors report that 
the omission of TBAs and other lay birth attendants from safe motherhood agendas will result in 
families that depend solely on SBAs, which remain in short supply.  These women will continue 
to experience increased maternal mortality and morbidity (Prata et al., 2011).  Due to weak 
political commitment and limited infrastructure, large regions exist without effective maternal 
mortality-reduction efforts in place.  Initiatives must include action at the policy level with a 
widening support base by influential stakeholders in the global effort to reduce the maternal 
mortality rate.  Education initiatives that target an increased utilization of prenatal, antenatal, and 
postnatal care should continue.  Prevention efforts must also continue.  The spectrum of agendas 
currently adopted by the most prominent and resource-rich agencies is broad in depth and 
breadth and should continue as well.  Initiatives that address transportation challenges, accurate 
measurement of blood loss, promotion of skin-to-skin contact following delivery and community 
education regarding poor birthing practices and family planning methods hold great merit, and 
these efforts must also persist.  
However, the use of misoprostol as a standalone intervention when appropriate is a 
promising approach to help facilitate the reduction of maternal deaths.  Improvements in health 
facilities and training of SBAs often benefit women who live in more developed areas but these 
advancements are not typically implemented to the scale necessary to reach women living in the 
most underdeveloped and least served areas (Prata et al., 2011).  In regions where there is 
already a measurable shift towards SBAs and emergency obstetric care, it is certainly prudent to 
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target investments with the goal of strengthening health facility access and care delivery.  This 
strategy will continue to augment the positive effects already seen in countries such as 
Afghanistan and Malawi.  Both countries have experienced a significant decline in maternal 
deaths since 1990 (WHO, 2012b).  The appropriate implementation of these interventions should 
be evaluated on a country-by-country basis.   
The impact of attempts to strengthen health systems may be inadequate in areas with the 
highest incidence of maternal death as a result of postpartum hemorrhage.  These are the very 
regions where the greatest potential exists to improve maternal and newborn survival.  As the 
challenges regarding access to quality care persist, the potential impact of community-based 
strategies show enormous promise.  Such community-based interventions will sustain mothers, 
promote maternal health and reduce preventable deaths.  Without appropriate government 
supported policy level implementation, such interventions will be difficult to achieve and 
impossible to maintain.  Some stakeholders may consider any diversion of maternal health 
resources from an agenda that emphasizes an increased use of skilled birth attendants as an 
improper use of resources, in light of inconsistent support of such strategies by organizations 
such as the WHO (Sutherland, Meyer, Bishai, Geller, & Miller, 2010).  
Access Barriers 
Postpartum hemorrhage accounts for nearly 25% of maternal deaths globally and is most 
likely to involve the poorest; most underserved, and marginalized women.  South Asia and Sub-
Saharan Africa comprises the greatest numbers of these women.  In countries most impacted by 
maternal deaths, the majority of pregnant women deliver at home without a skilled birth 
attendant present (Prata, Graff, Graves, & Potts, 2009).  Traditionally, births in these isolated, 
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rural communities occur without access to interventions should complications related to the birth 
arise.   
Transportation and communication systems are rudimentary at best, but more often they 
are absent altogether.  The lack of access to structured health facilities that possess necessary 
medications, health care worker skill set and supplies, in addition to a lack of skilled birth 
attendants are all factors which contribute to the complex issues surrounding effective treatment 
for these women (Geller, Adams, Kelly, & Kodkany, 2006).  Intervention programs will continue 
to have the greatest impact in remote, resource-poor areas in which transportation, geography 
and antenatal care pose significant challenges for pregnant women.  These remote areas are 
where maternal deaths occur with the greatest frequency.  As with many health care initiatives, 
without government level support, the chance of significantly impacting these statistics is 
remote.  
There are surprisingly significant success stories.  For example, the World Health 
Organization describes maternal mortality transport programs that began in 2006 to meet 
transportation needs related to access to comprehensive emergency obstetric care in Sierra Leone 
and Burundi (Medecins Sans Frontieres, 2012).  These programs have directly impacted maternal 
death rates in the above areas.  Regions in which maternal deaths are high often have unique 
challenges representative of the political and socioeconomic climate in their respective countries.  
In Sierra Leone and Burundi, a major barrier to restoring the heath care infrastructure is the lack 
of qualified medical personnel and poor geographic access to maternal services.  The Ministry of 
Health of Burundi, in collaboration with Medecins Sans Frontieres (MSF), a Belgium-based 
organization, have targeted these two barriers to access: implementing central referral facilities 
that provide emergency obstetric care together with an emergency ambulance transfer service in 
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order to bring women from outlying areas to the central facility.  Analysis shows that the 
introduction of emergency obstetric care and a referral system in regions in Burundi and Sierra 
Leone have rapidly and significantly decreased the number of maternal deaths.  These programs 
serve as a positive example of a model of care delivery that works for governments, donors and 
other NGO’s that are contemplating investment strategies (Medecins Sans Frontieres, 2012).  
Active Management of the Third Stage of Labor 
The single most effective strategy for preventing postpartum hemorrhage requires active 
management of the third stage of labor to include the use of drugs effective at stimulating uterine 
contraction known as uterotonics (Su, 2012).  Uterotonics save lives when administered 
appropriately to treat postpartum hemorrhage.  A recent Cochrane Review described the active 
management of the third stage of labor as a package that includes the administration of 
prophylactic uterotonics after birth, such as oxytocin, ergometrine and misoprostol; early cord 
clamping and cutting, and placental delivery by controlled cord traction.  While these techniques 
are described within the presence of skilled birth attendants, key principles of AMTSL are 
certainly applicable outside these settings (Oladapo et al., 2009).  The prevention of atonic 
postpartum hemorrhage via AMTSL has been promoted globally and is considered an evidence-
based intervention (Oadapo et al., 2009).  AMSTL reduces the incidence and severity of PPH 
and the need for blood transfusion or transfer to a referral facility (FIGO, SMNH, 2012).  Any 
program or intervention targeted at reducing death from PPH must include strategies to address 
AMTSL (Leduc, Senikas, & Lalonde, 2009).  Such programs have greatly impacted maternal 
deaths in countries such as Pakistan and Afghanistan, where policy-based programs have been 
undertaken with measurable success (Amowitz, Reis, & Iacopino, 2002).  Reductions in maternal 
mortality rates in these countries reflect these successes.  Prior to these programs, Pakistan and 
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Afghanistan possessed the highest maternal mortality rates worldwide (WHO, 2012b).  Such 
deaths are often preventable with a collaborative approach utilizing a variety of low-cost 
interventions, notably, the distribution of uterotonics prior to delivery. 
Programs aimed at routine use of AMTSL and the use of uterotonics refers to oxytocin as 
the first drug of choice.  Oxytocin, ergotamine and misoprostol are the three most widely 
recognized uterotonics in PPH treatment.  It is well documented throughout the literature that the 
widely accepted “gold standard” regarding uterotonics utilizes oxytocin, which requires skilled 
administration by injection as well as specific storage conditions.  The WHO specifically states 
any alternative uterotonic should be administered only when oxytocin is unavailable.  Oxytocin 
becomes an impractical solution due to a widespread insufficient cool/cold chain in low resource 
areas.  Oxytocin, along with other injectable uterotonics, requires refrigeration to maintain 
patency and injection safety, which is an enormous obstacle.  Additionally, ergotamine is 
contraindicated with pregnancy-induced hypertension (Sanghvi, Zulkarnain, & Chanpong, 2009).  
The lack of access to skilled care further inhibits the widespread use of oxytocin in low resource 
areas (Burchett & Mayhew, 2009).  It has only been recently that there have been notable strides 
to recognize the role misoprostol can play in maternal mortality reduction efforts (Derman et al., 
2006).  Many prominent experts in the field of maternal health have defined the administration of 
misoprostol in a low resource setting as a best practice for the prevention and treatment of 
postpartum hemorrhage (FIGO, SMNHC, 2012).  Misoprostol is a practical, cost-effective 
alternative to oxytocin.  The safety profile of misoprostol is superb, the cost minimal, and due to 
thermo stability properties, does not require refrigeration.  Additionally, misoprostol has proven 
to be stable under field conditions (United States Agency for International Development, 
[USAID], 2010).  In addition to treatment of postpartum hemorrhage, prophylactic misoprostol is 
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a “simple, inexpensive and highly effective therapy to prevent and manage PPH” (Diadhiou et 
al., 2011).  The 18
th
 Expert Committee on the Selection and Use of Essential Medicines 
approved the addition of misoprostol to the WHO approved model list of essential medicines in 
2011, further supporting its systematic distribution and continued use in previously described 
settings (FIGO, SMNHC, 2012).  
Safety and Efficacy 
Misoprostol is an inexpensive, thermostable prostaglandin E1 derivative.  It was 
originally approved for oral use to prevent and treat peptic ulcers associated with the use of 
nonsteroidal anti-inflammatory drugs.  It is a potent uterotonic and cervical priming agent, 
available in a tablet that can be administered multiple routes (Hofmeyr et al., 2009).  The oral 
and sublingual route results in the fastest onset of action and strongest initial uterotonic effect.  
Misoprostol is widely used for induction of abortion, cervical ripening, and induction of labor 
(Feitsma & Kanahi, 2005).  The most common side effects associated with the use of 
misoprostol include fever, chills, shivering, abdominal pain, nausea, vomiting and diarrhea.  Rare 
but serious side effects include uterine rupture and separation of cesarean scar; however, these 
effects are typically dose dependent (Burns, 2005).  Based on evidence to date, the role that 
misoprostol can play in the reduction of maternal deaths is significant.  This role could be 
elevated to that of life saving with urgent attention by those positioned to affect policymakers 
and the coordination of international NGO’s.  As illustrated in Table 1, the relative benefits of 
misoprostol use are substantial when compared to those of oxytocin and ergometrine.  
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Table 1 
Comparison of the Three Most Common Uterotonics and Their Relative Benefits 








Effectiveness +++ -/? ++ 
Requires Skilled 
Provider 
Yes No No 
Preparation Suitable 
for Home Birth 
No Yes Yes 
Serious Side Effects Rare Common Rare 
Contraindications 0% 15% 0% 
Heat Stability No No Yes 
Cost $0.80 $0.30-$0.50 $0.35-$0.50 
Source: Sanghvi, Zulkarnain, & Chanpong, 2009 
WHO Position Regarding Misoprostol 
It becomes quickly evident that misoprostol is appropriate in both preventative and 
treatment strategies for postpartum hemorrhage.  The WHO has taken an ambiguous and 
conservative stance regarding the use of misoprostol however, and guidelines updated as recently 
as 2011 state “there is still some uncertainty regarding the most effective dose and route of 
administration for the prevention and treatment of PPH” despite evidence to the contrary (World 
Health Assembly [WHA], 2011, p. 89).  In 2009 the Expert Committee requested an Expert 
Review to include the latest safety data and data from on-going community trials (WHA, 2011).  
Gynuity Health Projects and Venture Strategies for Health submitted an updated application for 
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the inclusion of misoprostol as an individual medicine on the WHO Essential Medicines List.  
The Committee chose not to list treatment of PPH in the list of conditions in which misoprostol 
is indicated (WHA, 2011).  Misoprostol is currently included on the Essential Medicines List for 
use in induction of labor, for termination of pregnancy in combination with mifepristone, “where 
legally permitted and culturally acceptable, and for the management of incomplete abortion and 
miscarriage” (WHA, 2011, pg. 87).  The WHO states, “to recommend misoprostol for prevention 
and treatment of PPH could divert attention or reduce attempts to implement oxytocin 
availability, a superior treatment” (WHA, 2011, pg. 90).  The lack of vigorous support of 
misoprostol as a key therapy to treat PPH remains a significant barrier in the expansion of 
misoprostol distribution programs.  The WHO also states that misoprostol “should be offered by 
a health worker trained in its use for prevention of PPH” (WHA, 2010, pg. 1).  Furthermore the 
WHO emphasizes that this recommendation has been misinterpreted as a “recommendation for 
community distribution during pregnancy (i.e. advance provision) for use when the need arises 
after birth” (WHA, 2011, pg. 1).  The WHO goes on to state that recent data “suggest there may 
be a benefit from use of misoprostol by traditional birth attendants or assistants provided with 
training on the use of the product at home deliveries” (WHA, 2011, pg. 88).  These statements by 
the WHO lend to the uncertainty in prioritizing the allocation of already scarce resources by 
policy makers.  Community distribution and administration of misoprostol both singularly and in 
conjunction with other initiatives has already been successfully implemented and supporting data 
demonstrates this success.  There have been dozens of randomized trials with more than 30,000 
women assessing the efficacy of misoprostol for prophylaxis (Sutherland et al., 2010).  Previous 
studies have demonstrated repeated success in the reduction of maternal deaths with programs 
that include distribution of misoprostol at the community level.  Until the WHO offers 
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resounding support of community based implementation programs, the lives of mothers will be 
lost. 
The Promise of Community Based Programs 
In the past, interventions have included an emphasis on increasing access to skilled birth 
attendants (SBAs).  However, in those countries that demonstrate a high maternal mortality ratio, 
the ratio of skilled birth attendants to women remains low and progress to increase access is slow 
(Prata et al., 2012).  Previous strategies have included the recruitment and retention of SBAs 
outside the areas that have the highest rate of maternal deaths in order to attempt to address the 
shortage.  Once they are trained, SBAs are often hesitant to work in these areas, and even if they 
are agreeable to working there, positioning them in these remote areas may not be cost-effective 
for many programs.  Costs related to empowering these communities can be far less than 
programs designed to place and retain SBAs, and will require no financial incentives in order to 
retain skilled as well as community birth attendants to remain in their own communities (Prata et 
al., 2011).  The goal of large-scale implementation of such interventions becomes more plausible 
when such factors are considered and applied to newer strategies.  It has only been in recent 
years that community-based distribution of misoprostol has been evaluated alone for its 
effectiveness in the treatment of postpartum hemorrhage.  Additionally, including community-
based birth attendants or traditional birth attendants (TBAs) in the safe motherhood agendas 
currently underway will assist in ensuring access to life-saving technologies and practices to 
women in remote areas.  Training of TBAs on distribution of misoprostol in conjunction with 
other interventions such as blood loss measurement tools has great potential to reduce maternal 
mortality and morbidity in those areas that are most underserved.  This task shifting strategy will 
continue to encounter barriers to its implementation without support by the WHO.  
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Task Shifting Strategies 
Any community-based success will only come with necessary supporting policy 
considerations at the government level as well as collaboration with those agencies most 
influential globally, such as the WHO.  Because access to SBAs is in the remote future at best for 
many of these areas of the world, a formal process of intentional and structured task shifting 
could be explored by agencies positioned to impact maternal deaths the greatest.  “According to 
the WHO, task shifting is the process of delegation whereby tasks are moved, where appropriate, 
to health workers with shorter training and fewer qualifications” (WHO, 2008, pg. 13).  Task 
shifting can occur within a clinical setting or can be comprised of the shifting of responsibilities 
from facility-based to community-based providers (Prata et al., 2012a).  A recent Cochrane 
Review called for increased research on low cost, low technological home based management of 
postpartum hemorrhage (Sibley et al., 2007).  Such simple, low-cost methods serve as an interim 
approach to improving maternal health while longer-term and sustainable strategies are slowly 
being implemented.  Many conventional programs focused exclusively on increasing access to 
skilled birth attendants with the use of TBAs in the role of advocates for skilled care only.  TBAs 
were utilized in a role that primarily urged women to obtain antenatal, obstetric and postnatal 
care, with little effort in expanding the knowledge base and skill set of TBAs.  Similar 
interventions have been included in many global initiatives directed at the reduction of the 
maternal mortality ratio worldwide.  These examples highlight the need for a comprehensive 
approach, rather than the singular focus on agenda items as seen previously.  
Task shifting strategies could be considered in order to successfully carry out such wide 
scale interventions.  The development of programs that facilitate the community-based 
distribution of misoprostol represents just such an opportunity to apply task shifting strategies.  
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The incidence of maternal deaths can be significantly reduced through the integration of and 
expansion of the scope of practice of TBAs through task-shifting efforts.  
Other healthcare interventions related to HIV and malaria has already revealed 
substantial gains by incorporating task shifting to improve access to services and mitigate the 
shortage of health professionals.  There are several examples in which task shifting strategies 
have resulted in success.  There have been recent successes that suggest such global 
collaboration is becoming more prominent.  Models used to combat malaria and HIV/AIDS, may 
provide a successful template for further success, and have demonstrated substantial 
improvements in patient outcomes, but strategies such as this would benefit from continued 
research (Brentlinger et al., 2010).  Only recently has the attention surrounding such 
underutilized technologies been redirected from the debates surrounding the knowledge and 
abilities of trained TBAs and the potential of empowering women to help themselves (Prata et 
al., 2011).  
Task shifting as a strategy has demonstrated a long history of success in Uganda.  The 
Ministry of Health adopted task shifting as a formal strategy as early as 1918.  The 
socioeconomic landscape of Uganda has many similarities related to health care challenges faced 
by its neighbors, including maternal health.  Uganda has a current maternal mortality ratio of 310 
per 100,000 live births (WHO, 2012b), which is significantly lower than surrounding countries.  
For example, Burundi, which is just 300 miles from Uganda, possesses a maternal mortality ratio 
of 800 per 100,000 live births (WHO, 2012b).  Strides in maternal death reduction efforts in 
Uganda can be attributed to the government’s role in early task shifting efforts.  The Ugandan 
Health Service introduced the use of a core group of medical professionals known as “licentiates, 
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later medical assistants, and currently known as clinical officers” (Dambisya & Matinhure, 
2012).  
The arena of pharmaceutical services has also been augmented with the use of such 
medical support staff in Uganda.  Additionally, a second level of task shifting involves the use of 
patient relatives and/or family members.  These individuals are known as “attendants” and often 
assist with activities of daily living such as feeding and bathing, as well as lab collection and 
medication retrieval for in-patients (Dambisya & Matinhure, 2012).  Task shifting has been 
demonstrated at the village level in Uganda with the implementation of the National Malaria 
Control Programme, which introduced the role of the “Community Medicine Distributor” 
working to manage fevers at the home level.  The Community Medicine Distributors are village 
based volunteers trained to identify and treat simple fevers in children, as well as identify more 
serious complications associated with malaria such as vomiting and diarrhea, poor feeding and 
seizure activity (Dambisya & Matinhure, 2012).  These volunteers are also responsible for 
medication administration protocols that have been simplified with pre-packaged, color coded 
dosing guidelines delineating age-specific treatment.  The success achieved at the village level 
with the home-based management of fever (HBMF) regimen resulted in a modified version of 
the program implemented in 2009 at the national level (Dambisya & Matinhure, 2012).  
A recent study conducted in 2011 in Bangladesh challenged previously held theories 
regarding the benefits related to the training of TBAs in the use of misoprostol (Prata et al., 
2012b).  Previous program failures were transformed with the advent of community-level 
implementation of misoprostol to include education initiatives of TBAs.  An evaluation study 
was conducted in rural Bangladesh from July 2009-January 2011.  This study utilized a two-day 
training period regarding misoprostol use and delivery mats.  Training was provided by four 
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physicians and included information on misoprostol function, dosage, and timing of 
administration, side effects and their management.  The training also provided information on 
early identification of high-risk pregnancies, danger signs of maternal infection and PPH with 
particular attention given to PPH. 
Prior to the training, very few TBAs identified misoprostol as means to prevent PPH and 
88.5% stated that they did not have any knowledge regarding the prevention of excessive 
bleeding (Prata et al., 2012b).  Post training of the TBAs found the training to be highly effective 
and the vast majority of TBAs attending home births safely and correctly utilized the two 
interventions.  Follow-up data eighteen months after the training showed adherence to protocols 
and knowledge retention remained high (Prata et al., 2012b).  A similar task-shifting model as 
seen with malaria programs can easily be translated for use with a misoprostol distribution 
program and efforts to do so should be explored (Cruz & McPake, 2011).  Incorporating the use 
of relatives and local village volunteers additionally ensures that traditional practices and beliefs 
are incorporated into any community-wide intervention.  This integration ensures that local 
customs surrounding birthing practices and the long-accepted knowledge held by TBAs is 
incorporated into any education programs and initiatives undertaken as recommended (Byrne & 
Morgan, 2011).  Such examples of success provide a roadmap (Harper, 2010) for similar task 
shifting efforts related to misoprostol distribution and administration programs.  Task shifting is 
not without challenges however.  Identified barriers related to the implementation of task shifting 
programs include the disparity between the knowledge base held by policy makers and front-line 
health workers in regards to the meaning and purpose of task shifting initiatives.  These barriers 
included front-line workers resistance to change (Teela et al., 2009), protection of role 
delineation by professionals, professional boundaries and regulations, high disease burden, heavy 
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workload, poor planning strategies and lack of clear cut guidelines regarding task shifting at the 
formal and policy level.  Many of these barriers have been overcome with the well-documented 
examples of other successful task shifting programs at the village or community level (Dambisya 
& Matinhure, 2012).  Because it is unlikely that the majority of women will have access to care 
from skilled birth attendants in the near future, governments, international agencies and local 
efforts need to bring interventions such as the community-based distribution of misoprostol to 
these women.  Future strategies should include TBAs as well as other community members who 
attend births, and delivering mothers themselves.  If both community and home-based 
management strategies for postpartum hemorrhage are to be implemented to the scale necessary 
to impact current maternal mortality rates, the approach surrounding effective interventions must 
be broadened.  
Cost Effectiveness 
 Health planners in low-resource settings face overwhelming funding constraints (Geller 
et al., 2008) and public health interventions, even lifesaving strategies, are often considered on 
the cost per life saved.  The cost-effectiveness of maternal health interventions is no exception 
and is a necessity for policy-makers.  An analysis conducted in 2010 evaluated the cost-
effectiveness of misoprostol for treatment versus prevention of PPH at the community or home 
level.  A simulation model was applied to portray mortality and morbidity caused by PPH among 
3 settings of 10,000 women delivering at home in rural India.  This setting is comprised of a 
large state in India with a high MMR and high home birth rate.  At the time of this simulation 
study, it was estimated that 71% of births in rural India occur at home (Sutherland et al., 2010).  
The simulation model included cost of drugs, birth attendant training and transport for 
women to obtain further emergency care if they did not respond to misoprostol.  The 3 scenarios 
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described were: 1) standard management as defined by delivery attendance by a TBA without 
medication availability, 2) standard management plus 800 micrograms of sublingual misoprostol 
for PPH treatment, and 3) standard management plus 600 micrograms of prophylactic oral 
misoprostol.  Results demonstrated a 70% lower mortality in the second setting and 81% lower 
mortality in the third setting (Sutherland et al., 2010).  The study results were used to calculate 
the cost-effectiveness of each intervention compared to no intervention.  Results showed the 
misoprostol treatment package saved 9.4 lives per 10,000 women when compared to standard 
management.  The prophylactic treatment package saves an additional 1.4 lives for a total of 10.8 
lives saved per 10,000 women.  The disease burden from maternal hemorrhage is calculated as 
325 DALY’s per 10,000 women with standard management with a reduction noted as low as 76 
DALY’s with misoprostol use.  The cost difference between standard management and treatment 
would be $1,212 per 10,000 women, while expansion to prevention would add another $5,721 
per 10,000 women (Sutherland et al., 2010).  Few public health interventions can prevent 
DALY’s as inexpensively.   
If incorporated with existing programs, the training of traditional birth attendants and 
mothers regarding the administration of misoprostol need not be costly (Bradley, Prata, Young-
Lin, & Bishai, 2007).  A cost-effectiveness study completed in 2007, determined the cost to train 
traditional birth attendants in the use of misoprostol for the treatment of postpartum hemorrhage 
per trainee, including teacher and materials.  The training and subsequent cost analysis occurred 
in Afghanistan in 1999 and in India in 2005.  Cost ranged from US $3 to $17 per trainee (Prata et 
al., 2011).  This study further substantiates the benefits of misoprostol use when the 
considerations center on training and program implementation cost containment.  When 
evaluating cost containment strategies related to treatment, again there are very few obstacles 
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identified.  The cost of a complete course of therapy utilizing misoprostol is approximately US 
$0.30 per woman (Rajbhandari et al., 2010).   
A recent cost-effectiveness modeling study of community-based distribution of 
misoprostol for home deliveries in a south Asian setting found it to be a cost-effective 
intervention, with a cost per death averted of $1,401 (Hussein, Newlands, D’Ambruoso, Thaver, 
Talukder & Besana, 2010).  Further support of such initiatives was demonstrated when, in 2006, 
The International Federation of Gynaecology and Obstetrics and the International Conference of 
Midwives jointly recommended the use of misoprostol for home births without a skilled 
attendant (Hussein et al., 2010).  A recent empirical study conducted in five communities near 
Zaria in the northwestern region of Nigeria (Prata et al., 2012a) demonstrated the feasibility and 
safety of the distribution of misoprostol on a large scale, in part, due to the well-executed 
community mobilization in order to implement a pre-determined health intervention.  
An operations research study conducted in Nepal from January 2006 through June 2008 
(Rajbhandari et al., 2010) implemented a misoprostol distribution program at a district level 
within the government health system.  The goal was to determine if high coverage, specifically 
among those at greatest risk, was feasible.  The components of disadvantage assessed included 
literacy, income and geographic isolation.  Program monitoring data concluded that program 
feasibility was established with relative ease.  Ending survey data showed that 18,761 women, 
over 74 percent of women previously identified as high risk that underwent vaginal births, 
received misoprostol.  Overall uterotonic coverage increased from 11.6% at the beginning of the 
study to 74.2% at its conclusion.  
A recent study conducted in Senegal further illustrates the ease of implementing a 
program to include misoprostol distribution at the community level.  This particular study 
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provides further evidence that the presence and supervision of skill birth attendants is 
unnecessary to successfully reduce maternal deaths with misoprostol administration for 
postpartum hemorrhage.  Senegal has a maternal mortality rate of 401 in 100,000 live births and 
only 33% of deliveries in the country are assisted by skilled attendants that would be considered 
qualified to prevent or treat obstetric complications (Diadhiou et al., 2011).  Data as recently as 
2011 states that 38% of women in Senegal deliver in their own homes or in the home of a friend 
or other family member (Diadhiou et al., 2011).  This study was conducted in two 
sociodemographically distinct poor regions of Senegal, where births seldom occur within the 
walls of health facilities or in the presence of skilled birth attendants.  The aim of the study was 
to demonstrate the effectiveness of a simple, low cost training program that would promote the 
safe and accurate administration of misoprostol by trained traditional birth attendants for 
prevention of postpartum hemorrhage.  Correct administration was clearly defined regarding oral 
dosing and timing during delivery.  Results were so overwhelming that the second planned study 
was cancelled on the basis of the results of the first study.  All study participants, whose 
deliveries were assisted by the traditional birth attendants that were trained for the purposes of 
the study, received correct and safe administration of misoprostol for postpartum hemorrhage 
prevention.  Training consisted of just one day supplemented by practicum as defined by 
attendance at ten deliveries at health centers and three deliveries at maternity huts (Diadhiou et 
al., 2011).  Additionally, the training incorporated education regarding the benefit or harm of 
controlled cord traction and uterine massage, as evidence related to these practices is sparse.  
Study participants were instructed to avoid both uterine massage and controlled cord traction 
during deliveries, with mixed compliance noted.  
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This illustrates the additional opportunities for the incorporation of adjunct interventions 
targeted at education related to poor birthing practices.  It is also feasible to incorporate protocols 
to include immediate arrangement of transportation and referral to available health centers for 
women requiring treatment for postpartum hemorrhage to include the use of misoprostol.  The 
support of simple training programs and unencumbered access to adequate supplies of 
misoprostol will make great strides to advance postpartum hemorrhage prevention and treatment 
in the community setting.  
Distribution Barriers 
There are several unique challenges related to misoprostol access for women that are 
underserved and high risk (Burns, 2005) as illustrated in Table 2.  Misoprostol has a complicated 
history and has been informally utilized for use in a diverse and broad sense, most notably 
associated with abortion.  As a result, despite the increasing body of evidence in support of the 
use of misoprostol, this proof has yet to result in consistent and effective policies, programs and 
clinical practice around the globe (Burns, 2005).  Its widespread policy implementation and use 
may provoke resistance among policy makers and providers and unwanted opposition and 
exposure from anti-abortion activists.  For example, the Ministry of Health in Brazil increased 
regulations in order to restrict the use of misoprostol as an abortifacient.  Several states enacted 
additional restrictions, with the state of Ceara issuing a complete ban on its use.  In countries 
where misoprostol is approved only for the prevention of gastric ulcers, use for obstetric or 
gynecological purposes is considered “off label” (Burns, 2005). 
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Table 2 
Perceived Barriers to Misoprostol Distribution at the Community Level Ranked in Order of 
Importance and Suggested Strategies 
Source: Coeytaux, & Wells, 2010 
 
Global Availability 
Challenges related to pharmaceutical strategies to reduce maternal deaths are not only 
related to access and the lack of development of new drugs in obstetrics.  Millennium 
Development Goal Eight encourages “global partnerships in cooperation with pharmaceutical 
companies provide access to affordable essential drugs in developing countries” (Fisk & Atun, 





1.  Lack of global consensus regarding 
evidence-based protocols and 
guidelines 
1.  Expand WHO guidelines related to misoprostol for PPH to include its 
use for treatment, not just prevention as well as more definitive statement 
regarding use at the community level. 
2.  Use of evidence-based advocacy; urge countries to think 
independently of WHO to make individual evidence-based decisions. 
3.  Encourage NGO coordination and cooperation; synchronize agendas 
and avoid duplication of efforts. 
 
2.  Association with abortion 1.  Focus messaging on value of misoprostol, lives saved. 
2.  Add misoprostol to safe delivery kits. 
3.  Control distribution of misoprostol to prevent “misuse” 
4. Consider legal challenge in countries with high MMR that restrict 
access to misoprostol. 
5.  Go “under the radar”. Introduce misoprostol for noncontroversial 
uses, with unspoken understanding that it may be used for abortion. 
 
3.  Concerns about safety and side 
effects 
 
1. Conduct additional, targeted research to include dosing, route of 
administration, and cost and benefit analysis. 
4.  Product issues 1.  Register specifically for postpartum hemorrhage. 
2. Ensure availability through private sector. 
 
5.  Controversy over who can 
administer misoprostol at the 
community level 
1.  Conduct research to address concerns regarding safety   and 
effectiveness of community level administration. 
2.  Increased emphasis on prevalence of home births. 
3.  Engage professional organizations as advocates. 
 
6.  Fear of women’s empowerment 1.  Target women as providers of their own care. 
2.  Utilize women’s organizations’ networks regarding availability and 
uses. 
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countries in pharmaceutical research and development, as well as global initiatives to impact 
disease burden in less developed countries, there is still a marked lack of new drugs for diseases 
of pregnancy.  Only one new class of drugs has been licensed in the past two decades, and no 
new class of drug is in clinical trials for primary obstetric uses (Fisk & Atun, 2008).  Although 
the effects of this shortage are noted in countries with readily available resources, the impact is 
much greater in resource-poor settings where the brunt of the disease and death burden is felt. 
Pregnancy is a temporary condition, thereby creating a relatively small market size.  
Unfortunately, without collaboration by pharmaceutical companies in research and development 
efforts, there is less likelihood of gaining the attention of international donor agencies.  The 
distribution of misoprostol should not be hampered, as the above challenges have been addressed 
successfully. 
 
Figure 1  
Global Misoprostol Registration by Indication. (Venture Strategies for Health and Development, 
2004) 
THE REDUCTION OF MATERNAL DEATHS WITH MISOPROSTOL 31 
Discussion and Recommendations 
Despite data demonstrating its effectiveness and cost-savings benefit, the widespread use 
of misoprostol especially in very low-resource locations remains controversial.  The lack of 
clear, evidence-based policies and guidelines has hindered policy makers in making sound 
decisions regarding the introduction of misoprostol at the national level.  The continued lack of 
clarity and vigor by the WHO guidelines regarding the use of misoprostol for prevention and 
treatment of PPH at the community level has further impeded efforts aimed at the reduction of 
maternal deaths due to postpartum hemorrhage.  This lack of clarity and guidelines has been 
cited as the single greatest barrier in community-based implementation programs (Coeytaux & 
Wells, 2011).  There is little research that has reported on the use of misoprostol used solely in 
the treatment or prevention of postpartum hemorrhage.  The few studies that have implemented 
misoprostol as a stand-alone strategy have all demonstrated its effectiveness in the treatment and 
prevention of PPH as well as its safety and usability in low resource areas.  This evidence has 
been shared along all appropriate academic, professional and clinical channels; yet progress in 
implementation remains slow.  The many studies that incorporated the use of misoprostol with 
other pharmacologic and non-pharmacologic interventions further substantiate the promise of 
expanding the role of misoprostol in PPH treatment and prevention.  Current strategies are 
fragmented and politicized, although access to misoprostol in recent years has shown a dramatic 
increase.  Task shifting strategies will play a crucial role to the successful implementation of 
community distribution programs and must be fully embraced by the international agencies best 
positioned to impact program implementation.  Such programs have been proven to save the 
lives of mothers in low resource areas where maternal deaths are the most profoundly 
experienced.  
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This systematic review has clearly identified the next steps if the global community is to 
achieve a significant reduction in maternal deaths. 
 The revision of the WHO position regarding indications for use of misoprostol to 
include PPH prevention and treatment. 
 The revision of the WHO position regarding community based distribution of 
misoprostol for PPH prevention with resounding advocacy for structured 
implementation of programs aimed at the training of TBAs in appropriate and timely 
misoprostol use. 
 Collaboration between the WHO, NGOs, the pharmaceutical industry and the 
governments of previously identified low resource countries and regions to develop 
and standardize the approach to addressing maternal deaths.  This approach should 
include community based distribution programs utilizing task shifting strategies 
discussed in this systematic review.  
 Continue the expansion of long term and sustainable strategies to reduce maternal 
deaths while simultaneously promoting policy advocacy related to community based 
misoprostol programs. 
The knowledge that maternal deaths can be averted with well-established evidence-based 
public health interventions is disturbing.  Yet, these deaths continue.  Quantifying losses when a 
mother dies goes beyond money or DALY’s prevented.  The fundamental human right of a 
woman’s health has been overlooked in favor of other high profile, palatable and often costly 
initiatives in the past.  The World Health Organization is urged to provide critical guidance to 
governments where maternal deaths continue unchecked.  With global alliances firmly in place 
and transparent policy development and implementation underway, maternal mortality initiatives 
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must now be scaled up to make a population level impact (Dieleman, Shaw, & Zwanikken, 
2011).  Such an impact is long overdue.  Although attainment of MDG 5 by the stated target 
dates is doubtful, global efforts must be increased to save the lives of mothers. 
Limitations 
 This analysis is a unique exploration of the use of misoprostol to reduce deaths from 
postpartum hemorrhage in low resource settings because it addresses both treatment and 
prevention strategies.  The progression and expansion of this analysis expanded far beyond the 
original scope of the investigation.  A comprehensive analysis of the pharmaceutical industry, 
specifically the sluggish development of obstetric drugs and the effects of the current business 
model employed by pharmaceutical companies would be beneficial; such analysis was beyond 
the scope of this systematic review.  Further examination of the political implications related to 
the implementation of maternal mortality intervention programs, specifically including conflict 
areas might have yielded more insights into public health outcomes.  Religious and cultural 
factors probably have significant implications in the development of any community based 
programs as well as deeply entrenched gender-based disparities, all which are often unique to 
global regions and political climate (Buse, Mays, & Walt, 2005) and also were not explored in 
depth as part of this investigation.  Further exploration of these crucial determinants is 
recommended.  
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Appendix A: Tier 1 Core Public Health Competencies Met 
Domain #1: Analytic/Assessment 
Identify the health status of populations and their related determinants of health and illness (e.g., factors 
contributing to health promotion and disease prevention, the quality, availability and use of health services) 
Describe the characteristics of a population-based health problem (e.g., equity, social determinants, 
environment) 
Identify sources of public health data and information 
Recognize the integrity and comparability of data 
Identify gaps in data sources 
Use information technology to collect, store, and retrieve data 
Describe how data are used to address scientific, political, ethical, and social public health issues 
Domain #2: Policy Development and Program Planning 
Gather information relevant to specific public health policy issues 
Describe how policy options can influence public health programs 
Explain the expected outcomes of policy options (e.g., health, fiscal, administrative, legal, ethical, social, 
political) 
Gather information that will inform policy decisions (e.g., health, fiscal, administrative, legal, ethical, social, 
political) 
Identify mechanisms to monitor and evaluate programs for their effectiveness and quality 
Domain #3: Communication 
Communicate in writing and orally, in person, and through electronic means, with linguistic and cultural 
proficiency 
Participate in the development of demographic, statistical, programmatic and scientific presentations 
Domain #4: Cultural Competency 
Recognize the role of cultural, social, and behavioral factors in the accessibility, availability, acceptability and 
delivery of public health services 
Domain #5: Community Dimensions of Practice 
Describe the role of governmental and non-governmental organizations in the delivery of community health 
services 
Domain #6:Public Health Sciences 
Identify the basic public health sciences (including, but not limited to biostatistics, epidemiology, environmental 
health sciences, health services administration, and social and behavioral health sciences) 
Describe the scientific evidence related to a public health issue, concern, or, intervention 
Retrieve scientific evidence from a variety of text and electronic sources 
Discuss the limitations of research findings (e.g., limitations of data sources, importance of observations and 
interrelationships) 
Domain #7: Financial Planning and Management 
Describe how cost-effectiveness, cost-benefit, and cost-utility analyses affect programmatic prioritization and 
decision making 
Domain #8: Leadership and Systems Thinking 
Identify internal and external problems that may affect the delivery of Essential Public Health Services 
Describe the impact of changes in the public health system, and larger social, political, economic environment 
on organizational practices 
 
